Peroxisome proliferator-activated receptor gamma agonist action of 3-methyl-1,2-cyclopentanedione

Biochimica et Biophysica Acta - General Subjects

Volumn 1770, Issue 12, 2007, Pages 1612-1619

  Choi, Seo Young ^a   Chung, Jae Heun ^a   Kim, Dae Hyun ^a   Chung, Sang Woon ^a   Kim, Ji Young ^a   Yu, Byung Pal ^b   Chung, Hae Young ^a  

^a Pusan National University   (South Korea)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

3 Methyl 1,2 cyclopentanedione; Coffee; Inflammation; NF B; PPAR agonist

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 3 METHYL 1,2 CYCLOPENTANEDIONE; CYCLOPENTANE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COFFEE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; ENDOTHELIUM CELL; ENZYME ASSAY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ANILIDES; ANIMALS; BLOTTING, WESTERN; CELL LINE; CYCLOPENTANES; DOWN-REGULATION; NF-KAPPA B; PPAR GAMMA; RATS;

EID: 35448952102     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.08.006     Document Type: Article

References (41)

1. Chung H.Y., Sung B., Jung K.J., Zou Y., and Yu B.P. The molecular inflammatory process in aging. Antioxid. Redox Signal. 8 (2006) 572-581
2. Je J.H., Lee J.Y., Jung K.J., Sung B., Go E.K., Yu B.P., and Chung H.Y. NF-κB activation mechanism of 4-hydroxyhexenal via NIK/IKK and p38 MAPK pathway. FEBS Lett. 566 (2004) 183-189
3. Tak P.P., and Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J. Clin. Invest. 107 (2001) 7-11
4. Jung K.J., Kim J.Y., Zou Y., Yu B.P., and Chung H.Y. Effect of short-term, low dose aspirin supplementation on the activation of pro-inflammatory NF-κB in aged rats. Mech. Ageing Dev. 127 (2006) 223-230
5. Lee J.Y., Yu B.P., and Chung H.Y. Activation mechanisms of endothelial NF-κB, IKK, and MAP kinase by tert-butyl hydroperoxide. Free Radic. Res. 39 (2005) 399-409
6. Bailey S.T., and Ghosh S. 'PPAR'ting ways with inflammation. Nat. Immunol. 6 (2005) 966-967
7. Bishop-Bailey D., Hla T., and Warner T.D. Intimal smooth muscle cells as a target for peroxisome proliferators-activated receptor-gamma ligand therapy. Circ. Res. 91 (2002) 210-217
8. Berger J., and Wagner J.A. Physiological and therapeutic roles of peroxisome proliferators-activated receptors. Diabetes Technol. Ther. 4 (2002) 163-174
9. Sung B., Park S., Yu B.P., and Chung H.Y. Modulation of PPAR in aging, inflammation, and calorie restriction. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 59 (2004) 997-1006
10. Houseknecht K.L., Cole B.M., and Steele P.J. Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest. Anim. Endocrinol. 22 (2002) 1-23
11. Hu E., Kim J.B., Sarraf P., and Spiegelman B.M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARgamma. Science 274 (1996) 2100-2103
12. Finck B.N., Han X., Courtois M., Aimond F., Nerbonne J.M., Kovacs A., Gross R.W., and Kelly D.P. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1226-1231
13. Gurnell M., Savage D.B., Chatterjee V.K., and O'Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J. Clin. Endocrinol. Metab. 88 (2003) 2412-2421
14. Tarrade A., Schoonjans K., Pavan L., Auwerx J., Rochette-Egly C., Evain-Brion D., and Fournier T. PPAR gamma/RXR alpha heterodimers control human trophoblast invasion. J. Clin. Endocrinol. Metab. 86 (2001) 5017-5024
15. Abe M., Hasegawa K., Wada H., Morimoto T., Yanazume T., Kawamira T., Hirai M., Furukawa Y., and Kita T. GATA-6 is involved in PPAR gamma-mediated activation of differentiated phenotype in human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 404-410
16. Akiyama T.E., Baumann C.T., Sakai S., Hager G.L., and Gonzalez F.J. Selective intranuclear redistribution of PPAR isoforms by RXR alpha. Mol. Endocrinol. 16 (2002) 707-721
17. Li L., Beauchamp M.C., and Renier G. Peroxisome proliferators-activated receptor alpha and gamma agonists upregulate human macrophage lipoprotein lipase expression. Atherosclerosis 165 (2002) 101-110
18. Sewter C.P., Blows F., Vidal-Puig A., and O'Rahilly S. Regional differences in the response of human pre-adipocytes to PPAR gamma and RXR alpha agonists. Diabetes 51 (2002) 718-723
19. Ciaraldi T.P., Cha B.S., Park K.S., Carter L., Mudaliar S.R., and Henry R.R. Free fatty acid metabolism in human skeletal muscle is regulated by PPAR gamma and RXR agonists. Ann. N.Y. Acad. Sci. 967 (2002) 66-70
20. Konturek P.C., Brzozowski T., Kania J., Bazela K., Kwiecien S., Harsch I., Konturek S.J., and Hahn E.G. Pioglitazone, a specific ligand of the peroxisome proliferators-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/reperfusion in rat. Scand. J. Gastroenterol. 38 (2003) 468-476
21. Sung B., Park S., Yu B.P., and Chung H.Y. Amelioration of age-related inflammation and oxidative stress by PPARgamma activator: suppression of NF-kappaB by 2,4-thiazolidinedione. Exp. Gerontol. 41 (2006) 590-599
22. Go E.K., Jung K.J., Kim J.Y., Yu B.P., and Chung H.Y. Betaine suppresses proinflammatory signaling during aging: the involvement of nuclear factor-kappaB via nuclear factor-inducing kinase/IkappaB kinase and mitogen-activated protein kinases. J. Gerontol., Ser. A, Biol. Sci. Med. Sci. 60 (2005) 1252-1264
23. Kim S.O., Kundu J.K., Shin Y.K., Park J.H., Cho M.H., Kim T.Y., and Surh Y.J. [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol ester-stimulated mouse skin. Oncogene 24 (2005) 2558-2567
24. Atanasov A.G., Dzyakanchuk A.A., Schweizer R.A., Nashev L.G., Maurer E.M., and Odermatt A. Coffee inhibits the reactivation of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: a glucocorticoid connection in the anti-diabetic action of coffee?. FEBS Lett. 580 (2006) 4081-4085
25. Kozuma K., Tsuchiya S., Kohori J., Hase T., and Tokimitsu I. Antihypertensive effect of green coffee bean extracts on mildly hypertensive subjects. Hypertens. Res. 28 (2005) 711-718
26. Kim A.R., Kim H.S., Choi J.S., Chang G.Y., Kim Y.J., and Chung H.Y. Selective peroxynitrite scavenging activity of 3-methyl-1,2-cyclopentanedione from coffee extract. J. Pharm. Pharmacol. 54 (2002) 1385-1392
27. Tada H., Shiho O., Kuroshima K., Koyama M., and Tsukamoto K. An improved colorimetric assay for interleukin 2. J. Immunol. Methods 93 (1986) 157-165
28. Lebel C.P., Ischiropoulos H., and Bondy S.C. Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. Chem. Res. Toxicol. 5 (1992) 227-231
29. Seimandi M., Lemaire G., Pillon A., Perrin A., Carlavan I., Voegel J.J., Vignon F., Nicolas J.C., and Balaguer P. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal. Biochem. 344 (2005) 8-15
30. Sanchez-Gomez F.J., Cernuda-Morollon E., Stamatakis K., and Perez-Sala D. Protein thiol modification by 15-deoxy-Delta12,14-prostaglandin J2 addition in mesangial cells: role in the inhibition of pro-inflammatory genes. Mol. Pharmacol. 66 (2004) 1349-1358
31. Marx N., Kehrle B., Kohlhammer K., Grub M., Koeing W., Hombach V., Libby P., and Plutzky J. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ. Res. 90 (2002) 703-710
32. Marx N., Schonbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83 (1998) 1097-1103
33. Planavila A., Laguna J.C., and Vazquez-Carrera M. Atorvastatin improves peroxisome proliferators-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappa B activation. Biochim. Biophys. Acta 1687 (2005) 76-83
34. Fujii H. Anti-inflammatory action of PPARs. Nippon Rinsho 63 (2005) 609-615
35. Jiang C., Ting A.T., and Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391 (1998) 82-86
36. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391 (1998) 79-82
37. Ricote M., Valledor A.F., and Glass C.K. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 230-239
38. Cronet P., Petersen J.F., Folmer R., Blomberg N., Sjoblom K., Karlsson U., Lindstedt E.L., and Bamberg K. Structure of the PPARalpha and-gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 9 (2001) 699-706
39. Hwang J., Kleinhenz D.J., Rupnow H.L., Campbell A.G., Thule P.M., Sutliff R.L., and Hart C.M. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vascul. Pharmacol. 46 (2007) 456-462
40. Chung J.H., Choi S.Y., Kim J.Y., Kim D.H., Lee J.W., Choi J.S., and Chung H.Y. 3-Methyl-1,2-cyclopentanedione down-regulates age-related NF-KB signaling cascade. J. Agric. Food Chem. 55 (2007) 6787-6792
41. Chung H.Y., Kim H.J., Kim K.W., Choi J.S., and Yu B.P. Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc. Res. Tech. 59 (2002) 264-272